Get the Stockscreener App
30.86
4.65%
1.37
After Hours:
30.97
0.11
+0.36%
Moderna Inc stock is traded at $30.86, with a volume of 9.15M.
It is up +4.65% in the last 24 hours and up +28.26% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$29.49
Open:
$29.83
24h Volume:
9.15M
Relative Volume:
0.87
Market Cap:
$12.06B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.5349
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-1.09%
1M Performance:
+28.26%
6M Performance:
+1.92%
1Y Performance:
-26.52%
1-Day Range:
$29.81
$31.34
1-Week Range:
$29.06
$31.34
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
30.86 | 11.52B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Victorville Daily Press
Moderna Vaccine (Spikevax): Why This COVID Shot Is Still at the Center of the Conversation - AD HOC NEWS
Moderna is rising today: what traders are watching (January 2) - Traders Union
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Lancaster Eagle-Gazette
Bank Pictet & Cie Europe AG Has $8.39 Million Position in Moderna, Inc. $MRNA - MarketBeat
The Truth About Moderna Inc (MRNA): Covid Hero Stock Or Price-Drop Trap? - AD HOC NEWS
Moderna’s Volatile Year: Can New mRNA Bets Revive MRNA’s Slumping Stock? - AD HOC NEWS
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Moderna to Host Investor Event – Analyst Day - Galesburg Register Mail
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Norwich Bulletin
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Chart of the Week: Moderna Stock May Be Finding a Bottom - Barron's
Legal Advantage Investments Inc. Takes $1.24 Million Position in Moderna, Inc. $MRNA - MarketBeat
Where Does Moderna Stock Rank Among Competitors? - Trefis
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Gadsden Times
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - South Bend Tribune
Cwm LLC Purchases 130,200 Shares of Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - Stock Traders Daily
mRNA Vaccine and Therapeutics Market is expected to reach US$ - openPR.com
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
Voya Investment Management LLC Decreases Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) News Today: Market Closed Sunday as Investors Weigh Friday Slide, Analyst Targets, and 2026 Catalysts - ts2.tech
TB Alternative Assets Ltd. Sells 602,072 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday - ts2.tech
Forget Moderna Stock, This is a Much Better Buy - Yahoo Finance
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts - ts2.tech
Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday? - Benzinga
Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts - MSN
Moderna: On Transition From Pandemic Windfall To Multi-Product Platform, Initiating At Neutral - Seeking Alpha
Massachusetts lands rare manufacturing wins from Moderna and Alnylam amid tariff push - The Business Journals
Corient Private Wealth LLC Has $1.54 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Biotech Stocks To Keep An Eye OnDecember 24th - MarketBeat
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets - ts2.tech
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna: Why I Am Selling The 'Relief Rally' (NASDAQ:MRNA) - Seeking Alpha
Moderna Stock (MRNA) Drops on Dec. 23, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Moderna (NASDAQ:MRNA) Trading Down 5.8%Here's Why - MarketBeat
Moderna price drops — what’s behind today’s move (December 23) - Traders Union
Moderna CEO Bancel holds expiring stock options, bets on drugmaker's recovery - The Business Journals
Thrivent Financial for Lutherans Has $2.57 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Fayetteville Observer
Moderna up almost 4%, looking to continue outperformance streak - TradingView — Track All Markets
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive - FinancialContent
COVID-19 Vaccine Market set for steady growth to US$ 29.98 - openPR.com
Moderna’s Strategic Moves Aim to Fortify Its Financial Future - AD HOC NEWS
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):